NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial

Completed · Phase 4 · Has a placebo group

Conditions studied: Epistaxis

In brief

The purpose of this research study is to determine whether Doxycycline can be used to control nosebleeds (epistaxis) for patients with Hereditary Hemorrhagic Telangiectasia (HHT). Patients with HHT will be randomized to one of 2 study arms: Doxycycline or Placebo for a period of 2 months followed by a 1-month washout period before switching treatments for a further 2 months period. Observation and evaluation will continue for a period of one month after treatment is completed.

Key facts

Study ID

NCT04167085

Run by

University of California, Los Angeles

People needed

26

Starts

2017-12-18

Expected to finish

2021-06-01

Last updated by the study team

2022-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of definite HHT by the Curacao criteria or genetic diagnosis of HHT
• Epistaxis severity during observation month at least moderate by Epistaxis Severity Score (ESS) evaluation
• For female participants, a negative pregnancy test at Day -1 and agree to use birth control during treatment and for 28 days following cessation of Doxycycline

You may not qualify if…

• Use of medication(s) contraindicated with doxycycline use within 14 days prior to the study (including barbiturates, tegretol, dilantin, warfarin, isotretinoin)

Where it is running

• 100 UCLA Medical Plaza — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.